• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A basic study of a new therapy based on an integrated cancer immune-genomic analysis for ovarian cancer

Research Project

Project/Area Number 16K15708
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Obstetrics and gynecology
Research InstitutionKyoto University

Principal Investigator

Koshiyama Masafumi  京都大学, 医学研究科, 客員研究員 (50724390)

Co-Investigator(Kenkyū-buntansha) 吉岡 弓子  京都大学, 医学研究科, 助教 (10402918)
安彦 郁  京都大学, 医学(系)研究科(研究院), その他 (20508246)
濱西 潤三  京都大学, 医学研究科, 講師 (80378736)
小西 郁生  京都大学, 医学研究科, 名誉教授 (90192062)
Project Period (FY) 2016-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords免疫ゲノミクス解析 / 機能ゲノム解析 / がん免疫機構 / T細胞解析 / 卵巣癌腹膜播種モデル / B7ファミリー / PD-1抗体 / PD-L1抗体 / 癌免疫 / 網羅的遺伝子変異解析 / 免疫細胞レパトア解析 / 網羅的遺伝子発現解析 / 免疫学 / ゲノム
Outline of Final Research Achievements

Using an ovarian cancer surgical specimen, we analyzed the pathologic changes and performed a T cell analysis before and after treatment. We recognized a consistent correlation between the changes in the T cell immunity state and the curative effect. Furthermore, we also identified specific molecules of the B7 family as immunologic factors, by comparing the pathologic changes before and after treatment with anticancer drugs using a mouse model of ovarian cancer peritoneum dissemination. We recognized that co-cultivating T cells for ovarian cancer cells expressing each gene induced these targets showed immunosuppressive activity. In addition, the T cells were re-activated when we suppressed the B7 family expression and inhibited the expression using a neutralizing antibody. In our in vitro mouse model of ovarian cancer, we demonstrated immunosuppressive activity similar to that observed in vitro and confirmed the prolonged survival by inhibition experiments using its antibody.

Report

(3 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • Research Products

    (4 results)

All 2017

All Journal Article (3 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 3 results,  Open Access: 3 results) Presentation (1 results)

  • [Journal Article] Potential efficacy of anti-PD-1 or PD-L1 antibody2017

    • Author(s)
      Koshiyama M
    • Journal Title

      Women’s Health open journal

      Volume: 3(3), Issue: 3 Pages: 21-23

    • DOI

      10.17140/whoj-3-e013

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.2017

    • Author(s)
      Koshiyama M, Matsumura N, Imai S, Yamanoi K, Abiko K, Yoshioka Y, Yamaguchi K, Hamanishi J, Baba T, Konishi I.
    • Journal Title

      Med Sci Monit.

      Volume: 23 Pages: 826-33

    • DOI

      10.12659/msm.899741

    • NAID

      120005997749

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Subtypes of ovarian cancer and ovarian cancer screening. Diagnostics2017

    • Author(s)
      Koshiyama M, Matsumura N, Konishi I
    • Journal Title

      Diagnostics

      Volume: 12 Issue: 1 Pages: 1-12

    • DOI

      10.3390/diagnostics7010012

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] Multi-omics analysis of anti-PD-1 antibody (Nivolumb) treated patients with ovarian cancer (PD-1経路阻害薬に対するマルチオミクス解析とバイオマーカー探索).2017

    • Author(s)
      Hamanishi J
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Annual Research Report

URL: 

Published: 2016-04-21   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi